Key result
Formulary Monograph Service provides monthly drug evaluations without reporting new clinical trial data.
Key points are not available for this paper at this time.
Design
Monograph service providing drug information and evaluations
Answers are grounded in this paper and cite their sources.
No trial data reported to inform formulary choices; leaves open evidence needs for hospital pharmacy decisions.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The June 2013 monograph topics are dimethyl fumarate (BG-12) delayed-release capsules, canagliflozin, ospemifene, aripiprazole extended-release injectable, and dabrafenib. The DUE/MUE is on dimethyl fumarate.
No takes yet. Share an insight, caveat, or question.
Cada et al. (2013) studied this question. The Formulary Monograph Service provides monthly drug monographs and utilization evaluations, with no clinical trial data reported in this abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: